Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer.

PHASE3CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
Transitional Cell Carcinoma of Urinary Bladder
Interventions
DRUG

Cisplatin

Weekly Cisplatin 35mg/m2 x 6 doses, IV administration

RADIATION

External beam radiation treatment

64Gy reference dose in 32 fractions over 6.5 weeks

Trial Locations (22)

1001

Auckland Hospital, Auckland

1871

Liverpool Hospital, Liverpool

2031

Prince of Wales Hospital, Randwick

2145

Westmead Hospital, Wentworthville

2298

Calvary Mater Newcastle, Newcastle

2751

Nepean Cancer Care Centre, Penrith

3002

Peter MacCallum Cancer Centre, East Melbourne

3181

Alfred Hospital, Prahran

3220

Andrew Love Cancer Care Centre, Geelong Hospital, Geelong

4029

Royal Brisbane Hospital, Herston

4102

Princess Alexandra Hospital, Woolloongabba

4120

Mater Centre - South Brisbane, Brisbane

4224

East Coast Cancer Centre, Tugun

4710

Christchurch Hospital, Christchurch

4814

Townsville Hospital, Douglas

5000

Royal Adelaide Hospital, Adelaide

6000

Royal Perth Hospital, Perth

6009

Sir Charles Gairdner Hospital, Nedlands

7250

Launceston General Hospital, Launceston

7902

Wellington Hospital, Wellington

Unknown

Dunedin Hospital, Dunedin

Palmerston North Hospital, Palmerston North

All Listed Sponsors
collaborator

National Health and Medical Research Council, Australia

OTHER

lead

Trans Tasman Radiation Oncology Group

OTHER

NCT00330499 - Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer. | Biotech Hunter | Biotech Hunter